国浩律师（上海）事务所 关于上海复星医药（集团）股份有限公司 实施差异化权益分派之 法律意见书 致：上海复星医药（集团）股份有限公司 国浩律师（上海）事务所（以下简称"本所"）接受上海复星医药（集团） 股份有限公司（以下简称"复星医药"或"公司"）的委托，就公司 2024 年度 实施差异化权益分派（以下简称"本次差异化分派"）事项，按照律师行业公认 的业务标准、道德规范和勤勉尽责精神，开展核查工作，出具本法律意见书。 第一节 引言 本所律师依据本法律意见书出具日以前已发生或存在的事实和中国现行法 律、法规和中国证券监督管理委员会的有关规定发表法律意见，并声明如下： 国浩律师（上海）事务所 法律意见书 （六）本所律师未授权任何单位或个人对本法律意见书作任何解释或说明； （七）本法律意见书仅供公司为本次差异化分派之目的使用，不得用作其 他任何用途。 2 （一）本所及本所律师依据《中华人民共和国证券法》《律师事务所从事证 券法律业务管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定 及本法律意见书出具日以前已经发生或者存在的事实，严格履行了法定职责， 遵循了勤勉尽责和诚实信用原则，进行了充分的核查验证，保 ...

Group 1 - The core viewpoint of the news is that the Shanghai Stock Exchange 300 Pharmaceutical Index has shown significant growth, with a 6.10% increase over the past month, 5.82% over the past three months, and 11.74% year-to-date [1] - The Shanghai Stock Exchange 300 Pharmaceutical Index is composed of listed companies in the pharmaceutical sector selected from the Shanghai and Shenzhen 300 Index, reflecting the overall performance of these companies [1] - The index was established on December 31, 2004, with a base point of 1000.0 [1] Group 2 - The top ten weighted companies in the Shanghai Stock Exchange 300 Pharmaceutical Index include: Heng Rui Medicine (42.46%), Pian Zai Huang (10.28%), Yunnan Baiyao (8.39%), Kelong Pharmaceutical (6.44%), East China Pharmaceutical (6.28%), New Hualian (5.68%), Fosun Pharmaceutical (5.54%), Baile Tianheng (4.14%), Tong Ren Tang (4.13%), and China Resources Sanjiu (3.51%) [1] - The market share of the index's holdings is 69.70% from the Shanghai Stock Exchange and 30.30% from the Shenzhen Stock Exchange [1] - The composition of the index's holdings by industry shows that drug formulations account for 64.85%, traditional Chinese medicine for 29.47%, and raw materials for 5.68% [1] Group 3 - The index sample is adjusted every six months, with adjustments implemented on the next trading day following the second Friday of June and December each year [2] - Weight factors are adjusted in accordance with the sample adjustments, which occur at the same time as the regular sample adjustments [2] - In special circumstances, the index may undergo temporary adjustments, such as when a sample company is delisted or undergoes mergers, acquisitions, or splits [2]

Group 1 - Hong Kong pharmaceutical stocks experienced a significant rise in the afternoon, with MicroPort Medical increasing by over 16% [1] - 3SBio saw an increase of over 8%, while WuXi Biologics rose by 4% [1] - Other companies such as China Resources Medical, WuXi AppTec, and Fosun Pharma also showed upward movement [1] Group 2 - Investors can buy Hong Kong stocks through A-share accounts without the need for the Hong Kong Stock Connect, allowing for T+0 trading [1]

港股医药股盘初拉升，微创医疗涨近10%，复星医药（600196）、药明康德（603259）、山东新华制药 （000756）股份、石四药集团上扬。 ...

Core Viewpoint - The "Tai Chi for the Elderly" initiative, a collaboration between Standard Chartered China and the Fosun Foundation, aims to promote health and wellness among senior citizens through Tai Chi practice and community engagement [3][4]. Group 1: Event Overview - The event took place on July 19 at the Lujiazui Financial City, where volunteers in Tai Chi uniforms guided elderly community members in practicing Tai Chi [3]. - The program has expanded from Shanghai to other cities like Beijing and Chengdu since its launch in 2024, with weekly sessions introduced to enhance participation [3]. Group 2: Volunteer Engagement - The number of Tai Chi volunteers from Standard Chartered has increased by 140% compared to the previous year, indicating a growing commitment to community service [3]. - Volunteers provided personalized instruction, correcting techniques and sharing health knowledge, which was well-received by the elderly participants [3]. Group 3: Community Impact - The event was held at the Le Lin 365 community center, which is focused on providing comprehensive elderly care services and is undergoing digital upgrades for better health management [4]. - The initiative emphasizes the importance of caring for the elderly today to ensure a better future for society, encouraging more organizations to participate in similar projects [4].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 新設控股子公司並實施跟投及激勵計劃暨關聯交易的公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025 年7 月2 2 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生、潘東輝先生及吳以芳先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生及楊玉成先生；以及本公司之職工 ...

二、H 股回购方案及实施情况 证券代码：600196 证券简称：复星医药 公告编号：临 2025-119 上海复星医药（集团）股份有限公司 关于回购实施结果暨股份结构变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示（简称同正文） ●截至 2025 年 7 月 21 日收市，A 股及 H 股回购方案实施期限均已届满，实施 情况如下： A 股回购方案 H 股回购方案 回购方案 2025/1/23 2025/1/23 首次披露日 回购方案 2025/1/22~2025/7/21 2025/1/22~2025/7/21 实施期限 （含收尾两日） 预计回购金额 人民币30,000万元~60,000万元 不适用 回购价格上限 人民币30元/股 不适用 □减少注册资本 包括但不限于注销或作为库存股 √用于员工持股计划或股权激励 份等 回购用途 √用于转换公司可转债 □为维护公司价值及股东权益 （上述二者之一或二者皆有） 实际回购股数 14,228,552股A 股 3,410,500 股 H 股 实际回购股数 0.53 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 回購實施結果暨股份結構變動的公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 * 僅供識別 证券代码：600196 证券简称：复星医药 公告编号：临 2025-119 上海复星医药（集团）股份有限公司 关于回购实施结果暨股份结构变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示（简称 ...

Core Viewpoint - Fosun Pharma is establishing a new nuclear medicine business platform, Xingrui Jingxuan, to enhance its innovative product pipeline and strengthen team cohesion and competitiveness [1][4]. Investment Structure - The initial registered capital of the new company is set at RMB 133.5 million, with contributions from Fosun Pharma and its subsidiaries, Chengdu Biocity Jingchuang Fund, co-investment platform, and incentive platform [1]. - The ownership distribution post-establishment will be approximately 89.89% for Fosun Pharma (or its subsidiaries), 2.62% for Chengdu Biocity Jingchuang Fund, 1.57% for the co-investment platform, and 5.92% for the incentive platform [1]. Co-Investment and Incentive Plans - A co-investment platform will be established with a total contribution of RMB 2.1 million from six participants, including senior management [2]. - An incentive platform will be created with an investment of RMB 7.9 million, which will be used for the initial incentive plan and potential future equity incentive plans [2][3]. Incentive Plan Details - The initial incentive plan will grant a total of 4.2 million options to six incentive targets, including senior management, with specific allocations for each [3]. - The options, if fully exercised, will correspond to RMB 4.2 million of the registered capital, representing approximately 3.15% of the initial registered capital of the new company [3]. Business Focus - The new company aims to develop integrated diagnostic and therapeutic nuclear medicine products in the oncology field through self-research and collaborative development [4].

证券代码：600196 证券简称：复星医药 公告编号：临 2025-119 上海复星医药（集团）股份有限公司 关于回购实施结果暨股份结构变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 以上详情请见 2025 年 1 月 23 日、2025 年 3 月 18 日于《中国证券报》《上海 证券报》《证券时报》和上海证券交易所网站（https://www.sse.com.cn）发布的 相关公告。 （二）A 股回购方案实施情况 重要内容提示（简称同正文） ●截至 2025 年 7 月 21 日收市，A 股及 H 股回购方案实施期限均已届满，实施 情况如下： | | A 股回购方案 | H 股回购方案 | | --- | --- | --- | | 回购方案 | 2025/1/23 | 2025/1/23 | | 首次披露日 | | | | 回购方案 | 2025/1/22~2025/7/21 | 2025/1/22~2025/7/21 | | 实施期限 | | | | （含收尾两日） | | | | 预计回购金额 | 人民币 ...